Nuveen
DNA icon

Nuveen’s Ginkgo Bioworks DNA Stock Holding History

Nuveen’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Sell
146,845
-34,904
-19% -$292K ﹤0.01% 2748
2026
Q1 		$1.11M Buy
181,749
+2,111
+1% +$17.6K ﹤0.01% 2533
2025
Q4 		$1.49M Buy
179,638
+120,819
+205% +$1.3M ﹤0.01% 2416
2025
Q3 		$858K Buy
58,819
+8,241
+16% +$98.6K ﹤0.01% 2691
2025
Q2 		$569K Buy
+50,578
New +$392K ﹤0.01% 2839
2024
Q3 		– Sell
-670
Closed -$8.96K – 3339
2024
Q2 		$8.96K Sell
670
-107,207
-99% -$3.2M ﹤0.01% 3327
2024
Q1 		$5.01M Buy
107,877
+89
+0.1% +$4.61K ﹤0.01% 1995
2023
Q4 		$7.29M Buy
107,788
+6,648
+7% +$407K ﹤0.01% 1772
2023
Q3 		$7.32M Buy
101,140
+11,398
+13% +$911K ﹤0.01% 1667
2023
Q2 		$6.68M Buy
89,742
+16,933
+23% +$1M ﹤0.01% 1756
2023
Q1 		$3.87M Buy
72,809
+18,221
+33% +$1.15M ﹤0.01% 2032
2022
Q4 		$3.69M Sell
54,588
-16,297
-23% -$1.5M ﹤0.01% 2084
2022
Q3 		$8.85M Buy
70,885
+30,979
+78% +$3.69M ﹤0.01% 1555
2022
Q2 		$3.8M Buy
+39,906
New +$4.87M ﹤0.01% 2130

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Nuveen's DNA Position: Q2 2026 in Review

Nuveen reduced its Ginkgo Bioworks (DNA) stake by 19% in Q2 2026, selling an estimated $292K and leaving 146,845 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2748.

Nuveen first reported a position in DNA in Q2 2022 and has held it in 14 quarters since. The position peaked at $8.85M in Q3 2022. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Nuveen held 146,845 shares of Ginkgo Bioworks worth $1.46M as of Q2 2026.
  • Nuveen sold 34,904 Ginkgo Bioworks shares in Q2 2026, an estimated $292K.
  • Ginkgo Bioworks made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2748 holding.
  • Nuveen first reported a position in Ginkgo Bioworks in Q2 2022 and has held it in 14 quarters since.
  • Nuveen's Ginkgo Bioworks position peaked at $8.85M in Q3 2022.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.